Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study

被引：0
|
作者：
Mok, T. [1 ]
Wu, Y. -L. [2 ,3 ]
Sadowski, S. [4 ]
Zhang, J. [5 ]
Rangwala, R. [4 ]
de Lima Lopes, G. [6 ,7 ]
机构：
[1] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[4] Merck & Co Inc, Clin Oncol, Kenilworth, NJ USA
[5] Merck & Co Inc, BARDS, Kenilworth, NJ USA
[6] Oncoclin Brasil Grp, Oncol, Sao Paulo, Brazil
[7] Johns Hopkins Univ, Sao Paulo, Brazil
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
481TiP
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042
    Mok, T.
    Wu, Y. -L.
    Sadowski, S.
    Zhang, J.
    Rangwala, R.
    Kush, D.
    de Lima Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S142 - S142
  • [2] Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894)
    Lopes, Gilberto De Lima
    Wu, Yi-Long
    Sadowski, Sara
    Zhang, Jin
    Rangwala, Reshma
    Kush, Debra
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S244 - S245
  • [3] KEYNOTE-042: PHASE 3 STUDY OF PEMBROLIZUMAB (MK-3475) VERSUS PLATINUM DOUBLET CHEMOTHERAPY AS FIRST-LINE THERAPY FOR PD-L1-POSITIVE NON-SMALL CELL LUNG CANCER
    Lopes, Gilberto
    Watson, Patricia A.
    Zhang, Jin
    Rangwala, Reshma
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S192 - S192
  • [4] Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-positive advanced non-small cell lung cancer (NSCLC).
    Mok, Tony
    Wu, Yi-Long
    Watson, Patricia A.
    Zhang, Jin
    Rangwala, Reshma A.
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%
    Lopes, G.
    Wu, Y.
    Kudaba, I.
    Kowalski, D.
    Cho, B.
    Turna, H.
    De Castro, G., Jr.
    Srimuninnimit, V.
    Laktionov, K.
    Bondarenko, I.
    Kubota, K.
    Lubiniecki, G.
    Zhang, J.
    Kush, D.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S152 - S152
  • [6] Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
    Mok, Tony S. K.
    Wu, Yi-Long
    Kudaba, Iveta
    Kowalski, Dariusz M.
    Cho, Byoung Chul
    Turna, Hande Z.
    Castro, Gilberto, Jr.
    Srimuninnimit, Vichien
    Laktionov, Konstantin K.
    Bondarenko, Igor
    Kubota, Kaoru
    Lubiniecki, Gregory M.
    Zhang, Jin
    Kush, Debra
    Lopes, Gilberto
    LANCET, 2019, 393 (10183): : 1819 - 1830
  • [7] KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1-positive NSCLC after platinum-based therapy
    Herbst, R. S.
    Kim, D-W.
    Felip, E.
    Perez-Gracia, J. L.
    Garon, E. B.
    Han, J-Y.
    Molina, J.
    Kim, J-H.
    Gervais, R.
    Ahn, M-J.
    Majem, M.
    Fidler, M. J.
    De Castro, G., Jr.
    Garrido, M.
    Lubiniecki, G. M.
    Shentu, Y.
    Im, E.
    Baas, P.
    ANNALS OF ONCOLOGY, 2015, 26 : 162 - 162
  • [8] Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
    Lopes, Gilberto
    Wu, Yi-Long
    Kudaba, Iveta
    Kowalski, Dariusz
    Cho, Byoung Chul
    Castro, Gilberto
    Srimuninnimit, Vichien
    Bondarenko, Igor
    Kubota, Kaoru
    Lubiniecki, Gregory M.
    Zhang, Jin
    Kush, Debra A.
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
  • [9] KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1).
    Brahmer, Julie R.
    Kim, Edward S.
    Zhang, Jin
    Smith, Margaret Marie
    Rangwala, Reshma A.
    O'Brien, Mary E. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+Locally Advanced/Metastatic NSCLC
    Cho, B. C.
    Wu, Y.
    Lopes, G.
    Kudaba, I.
    Kowalski, D. M.
    Turna, H. Z.
    De Castro, G., Jr.
    Caglevic, C.
    Zhang, L.
    Karaszewska, B.
    Laktionov, K. K.
    Srimuninnimit, V.
    Bondarenko, I.
    Kubota, K.
    Yin, L.
    Lin, J.
    Souza, F.
    Mok, T. S. K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S225 - S226
12345